Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Keros Therapeutics Inc | KROS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 57.72 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 57.72 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 27.02 - 73.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 57.72 | USD |
Keros Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.08B | 35.98M | - | 151k | -152.99M | -4.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Keros Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KROS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 55.05 | 59.67 | 53.24 | 57.05 | 287,219 | 2.67 | 4.85% |
| 1 Month | 64.19 | 65.57 | 53.24 | 58.49 | 279,954 | -6.47 | -10.08% |
| 3 Months | 51.54 | 73.00 | 50.10 | 63.02 | 351,285 | 6.18 | 11.99% |
| 6 Months | 29.39 | 73.00 | 27.31 | 50.76 | 394,566 | 28.33 | 96.39% |
| 1 Year | 45.86 | 73.00 | 27.02 | 46.29 | 302,763 | 11.86 | 25.86% |
| 3 Years | 59.59 | 73.00 | 24.38 | 45.31 | 222,812 | -1.87 | -3.14% |
| 5 Years | 20.10 | 88.80 | 20.10 | 47.08 | 198,474 | 37.62 | 187.16% |
Keros Therapeutics Description
| Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
